Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Markert

Showing results (1-10 of 196) with videos related to

Pageof 20
Sort By:
Acta Microbiologica Academiae Scientiarum Hungaricae|January 1, 1975
17Beta-hydroxysteroid dehydrogenase activity in Streptomyces hydrogenansC Markert, L Träger
Hoppe-Seyler'S Zeitschrift Fur Physiologische Chemie|December 1, 1975
[Enzyme induction in Streptomyces hydrogenans. V. Characterization of testosterone-17 beta-dehydrogenase and its induction by steroids]C Markert, L Träger
Hoppe-Seyler'S Zeitschrift Fur Physiologische Chemie|October 1, 1974
Proceedings: The testosterone 17beta-dehydrogenans. A comparison with 20beta-hydroxysteroid dehydrogenase from the same microorganismC Markert, B Betz, L Träger
Zeitschrift Fur Naturforschung. Section C, Biosciences|March 1, 1975
Testosterone metabolism in streptomyces hydrogenansC Markert, B Betz, L Träger
Journal of Virological Methods|October 21, 1998
Critical level and detection limit: performance measures for PCR-based assaysC Markert-Hahn, C Berding, C Kuhn
Cancer Research|December 1, 1978
Cellular binding proteins for vitamin A in colorectal adenocarcinoma of ratD E Ong, C Markert, J F Chiu
Digestion|January 1, 1978
Induction of colonic adenocarcinomas by 1,2-dimethylhydrazine intrarectally administered in ratsC Markert, L W Rogers, J F Chiu
Journal of Clinical Microbiology|March 21, 1998
Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assaysG Haberhausen, J Pinsl, C C Kuhn, et al.
Journal of the National Cancer Institute|August 1, 1979
Immunospecificity of nuclear nonhistone protein-DNA complexes in colon adenocarcinomaJ F Chiu, W Decha-Umphal, C Markert, et al.
Clinical Pharmacology and Therapeutics|September 20, 2013
CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteersC Markert, J Burhenne, J Weiss, et al.
Pageof 20

Showing results (1-10 of 196) with videos related to

Sort By:
Pageof 20
Acta Microbiologica Academiae Scientiarum Hungaricae|January 1, 1975
17Beta-hydroxysteroid dehydrogenase activity in Streptomyces hydrogenansC Markert, L Träger
Hoppe-Seyler'S Zeitschrift Fur Physiologische Chemie|December 1, 1975
[Enzyme induction in Streptomyces hydrogenans. V. Characterization of testosterone-17 beta-dehydrogenase and its induction by steroids]C Markert, L Träger
Hoppe-Seyler'S Zeitschrift Fur Physiologische Chemie|October 1, 1974
Proceedings: The testosterone 17beta-dehydrogenans. A comparison with 20beta-hydroxysteroid dehydrogenase from the same microorganismC Markert, B Betz, L Träger
Zeitschrift Fur Naturforschung. Section C, Biosciences|March 1, 1975
Testosterone metabolism in streptomyces hydrogenansC Markert, B Betz, L Träger
Journal of Virological Methods|October 21, 1998
Critical level and detection limit: performance measures for PCR-based assaysC Markert-Hahn, C Berding, C Kuhn
Cancer Research|December 1, 1978
Cellular binding proteins for vitamin A in colorectal adenocarcinoma of ratD E Ong, C Markert, J F Chiu
Digestion|January 1, 1978
Induction of colonic adenocarcinomas by 1,2-dimethylhydrazine intrarectally administered in ratsC Markert, L W Rogers, J F Chiu
Journal of Clinical Microbiology|March 21, 1998
Comparative study of different standardization concepts in quantitative competitive reverse transcription-PCR assaysG Haberhausen, J Pinsl, C C Kuhn, et al.
Journal of the National Cancer Institute|August 1, 1979
Immunospecificity of nuclear nonhistone protein-DNA complexes in colon adenocarcinomaJ F Chiu, W Decha-Umphal, C Markert, et al.
Clinical Pharmacology and Therapeutics|September 20, 2013
CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteersC Markert, J Burhenne, J Weiss, et al.
Pageof 20